

Supplemental material**Supplemental Table 1 Comparison of study characteristics between 4S and TIMS-CHINA**

	4S N=2370	TIMS-CHINA N=1109	P
Median Age, yr	65	64.5	0.0077
Sex: Male	66.9%	60.6%	0.0003
Median NIHSS at baseline, points	7	11	0.0000
Median Onset to needle, hours	2.83	2.83	0.0566
% of lower dose	10.1	16.8	0.0000
Median dosage/ per kg	0.9	0.9	0.1779
%History of Hypertension	60.6	59.2	0.4272
%History of Diabetes	22.2	17.5	0.0015
%History of Previous Stroke	9.8	18.6	0.0000
%History of smoking	38.7	40.0	0.4717
%History of atrial fibrillation	16.8	18.2	0.3241
% of sICH in 36h	4.3	4.3	0.9953

NIHSS=National Institution of Health Stroke Scale; sICH=symptomatic intracranial hemorrhage

Supplemental Table 2. Dynamic dosage on the efficacy and safety outcome in acute ischemic stroke

Group^{&}	dosage	sICH		Favorable outcome[#]			
		mg/kg	HR	95%CI	HR	95%CI	
<i>Mild stroke</i>	tpa 0.9	0.017	0.009 0.029	0.669	0.634 0.703		
	tpa 0.8	0.016	0.000 0.087	0.633	0.499 0.754		
	tpa 0.7	0.083	0.010 0.269	0.625	0.406 0.812		
	tpa 0.6	NA	NA 0.195	0.688	0.413 0.890		
	tpa 0.5	0.25	0.006 0.805	0.333	0.008 0.906		
<i>Moderate Stroke</i>	tpa 0.9	0.036	0.028 0.047	0.593	0.568 0.618		
	tpa 0.8	0.008	0.000 0.046	0.624	0.530 0.712		
	tpa 0.7	0.015	0.000 0.083	0.508	0.381 0.634		
	tpa 0.6	NA	NA 0.161	0.524	0.298 0.743		
	tpa 0.5	NA	NA 0.410	0.714	0.290 0.963		
<i>Severe stroke</i>	tpa 0.9	0.081	0.062 0.104	0.661	0.623 0.698		
	tpa 0.8	0.130	0.054 0.249	0.696	0.542 0.823		
	tpa 0.7	0.143	0.040 0.327	0.640	0.425 0.820		
	tpa 0.6	0.167	0.021 0.484	0.500	0.187 0.813		
	tpa 0.5	0.091	0.002 0.413	0.600	0.262 0.878		

[&]Group: Mild= NIHSS 0-4, Moderate=NIHSS 5-14, Severe=NIHSS ≥15

[#]Favorable outcome: 7days after onset, the NIHSS of patient has improved to 0 or 1, or decrease 4 points compared to baseline NIHSS score.

NA: Not available due to limited data.

Supplemental Table 3 Comparison demographics and outcome between mild-moderate stroke and severe stroke subgroups

	Mild-Moderate stroke	Severe stroke	P
N=807			
N=2649			
<hr/>			
Number of lower dosage(%)	318(12.00)	105(13.01)	0.4823
<hr/>			
Age			<0.0001
<45yr, n	134	17	
45-64yr, n	1267	269	
≥65yr, n	1229	515	
Gender: Male, n(%)	1776(67.04)	463(57.37)	<0.0001
Median Onset to needle, hours	2.833	2.667	<0.0001
<hr/>			
History and Risk Factors			
Hypertension, n(%)	1577(59.53)	503(62.33)	0.1675
Diabetes, n(%)	569(21.25)	156(19.33)	0.2592
Previous Stroke, n(%)	302(11.4)	132(16.36)	0.0003
TIA, n(%)	88(3.32)	37(4.58)	0.1154
Atrial Fibrillation, n(%)	325(12.27)	273(33.83)	<0.0001
<hr/>			
Outcome			
sICH, n(%)	76(2.87)	71(8.80)	<0.0001
Clinical Improvement, n(%)	1582(59.72)	475(58.86)	0.0350
<hr/>			

Group: Mild-Moderate=NIHSS 0-14, Severe=NIHSS ≥15

TIA=*transient ischemic attack*, sICH=*symptomatic intracranial hemorrhage*

Supplemental Figure 1. Histogram of alteplase dosage